 |
|
|
| |
Raltegravir 1200 mg Once Daily Versus Raltegravir 400 mg Twice Daily, in Combination With Tenofovir
Disoproxil Fumarate/Emtricitabine, in Previously Untreated HIV-1 Infection Through Week 96
|
| |
| |
Reported by Jules Levin
9th International AIDS Society (IAS) Conference on HIV Science, Paris, France, 23-26 July 2017
Pedro Cahn1; Richard Kaplan2; Paul Sax3; Kathleen Squires4; Jean-Michel
Molina5; Winai Ratanasuwan6; Mohammed Rassool7; Xia Xu8; Yan Zhou8;
Brenda Homony8; Deborah Hepler8; Hedy Teppler8; George Hanna8;
Bach-Yen Nguyen8; Wayne Greaves8; for the ONCEMRK Study Group
1Fundacion Huesped, Buenos Aires, Argentina; 2Desmond Tutu HIV Foundation, Cape Town,
South Africa; 3Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA;
4Thomas Jefferson University, Philadelphia, PA, USA; 5University of Paris Diderot, Hopital
Saint-Louis, Paris, France; 6Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok,
Thailand; 7University of Witwatersrand, Helen Joseph Hospital, Johannesburg, South Africa;
8Merck & Co., Inc., Kenilworth NJ, USA
|
| |
|
|
|
|
|
